DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
QUEST DIAGNOSTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$234.91−0.09 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $26.31B
- P/E (TTM)
- 25.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.1%
105M of 110M shares
Institutional holders
1,105
118 new, 70 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 29 sales
Net sold $37.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,308,815 | 8.40% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 8,274,567 | 7.53% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 6,096,629 | 5.54% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,275,411 | 8.40% | $1.97B | +103,119 | 0.03% |
| Vanguard Capital Management LLC | 7,233,394 | 6.55% | $1.53B | +87,722 | 0.03% |
| Vanguard Portfolio Management LLC | 6,131,045 | 5.55% | $1.30B | +49,645 | 0.06% |
| State Street Corp | 5,516,643 | 5.00% | $1.17B | +135,822 | 0.03% |
| Price T Rowe Associates Inc /Md/ | 5,444,986 | 4.93% | $1.15M | −853,001 | 0.12% |
| Boston Partners | 4,744,473 | 4.30% | $1.00B | +732,241 | 0.89% |
| JPMorgan Chase & Co | 3,520,438 | 3.19% | $748.59M | −326,018 | 0.04% |
| Geode Capital Management, LLC | 3,137,873 | 2.84% | $662.58M | +51,565 | 0.04% |
| Morgan Stanley | 2,460,497 | 2.23% | $521.50M | −19,223 | 0.03% |
| EdgePoint Investment Group Inc. | 2,247,568 | 2.04% | $476.37M | +3,699 | 3.60% |
| Dimensional Fund Advisors LP | 1,988,048 | 1.80% | $421.38M | +38,513 | 0.08% |
| Bank Of America Corp /De/ | 1,935,133 | 1.75% | $410.15M | +182,231 | 0.03% |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1,888,207 | 1.71% | $400.21M | +5,183 | 0.90% |
| Wells Fargo & Company/Mn | 1,751,220 | 1.59% | $371.17M | −11,549 | 0.06% |
| Davis Selected Advisers | 1,555,612 | 1.41% | $329.78M | −62,201 | 1.42% |
| Victory Capital Management Inc | 1,550,556 | 1.40% | $328.64M | −295,780 | 0.18% |
| Norges Bank | 1,406,620 | 1.27% | $298.13M | New | 0.03% |
| FMR LLC | 1,398,735 | 1.27% | $296.46M | +456,517 | 0.01% |
| Invesco Ltd. | 1,379,115 | 1.25% | $292.30M | −259,372 | 0.02% |
| Northern Trust Corp | 1,127,454 | 1.02% | $238.96M | +13,235 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,105 | 105M | 95.1% | 118 / 430 | 352 / 70 | 8M | 5M |
| Q1 2026 | 1,069 | 103M | 93.0% | 123 / 350 | 384 / 89 | 19M | 8M |
| Q4 2025 | 1,050 | 107M | 96.5% | 149 / 349 | 347 / 90 | 10M | 13M |
| Q3 2025 | 1,006 | 109M | 99.0% | 115 / 359 | 342 / 82 | 10M | 9M |
| Q2 2025 | 991 | 108M | 98.2% | 121 / 365 | 328 / 83 | 13M | 7M |
| Q1 2025 | 968 | 103M | 93.8% | 145 / 315 | 338 / 61 | 11M | 6M |
| Q4 2024 | 896 | 99M | 90.1% | 124 / 310 | 304 / 59 | 8M | 7M |
| Q3 2024 | 848 | 100M | 90.4% | 94 / 294 | 308 / 73 | 19M | 8M |
| Q2 2024 | 838 | 99M | 89.7% | 90 / 277 | 300 / 59 | 7M | 13M |
| Q1 2024 | 817 | 105M | 95.0% | 90 / 269 | 311 / 89 | 12M | 8M |
| Q4 2023 | 827 | 101M | 91.9% | 108 / 254 | 329 / 64 | 10M | 6M |
| Q3 2023 | 795 | 99M | 89.3% | 70 / 230 | 337 / 82 | 7M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,514,526 | 3.18% | $744.90M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,868,317 | 2.60% | $607.94M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 2,398,588 | 2.17% | $508.38M | 0.23% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,519,109 | 1.38% | $321.98M | 0.04% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,407,676 | 1.28% | $274.36M | 0.03% | May 31, 2026 |
| Disciplined Value Mid Cap Fund | 1,222,712 | 1.11% | $259.15M | 1.12% | Jun 30, 2026 |
| JPMorgan Equity Income Fund | 1,153,090 | 1.04% | $244.40M | 0.56% | Jun 30, 2026 |
| T. Rowe Price Dividend Growth Fund, Inc. | 1,109,242 | 1.00% | $235.10M | 0.99% | Jun 30, 2026 |
| Disciplined Value Fund | 1,064,982 | 0.96% | $225.72M | 1.15% | Jun 30, 2026 |
| Victory Sycamore Established Value Fund | 1,055,000 | 0.96% | $223.61M | 1.45% | Jun 30, 2026 |
| Vanguard Value Index Fund | 1,052,676 | 0.95% | $223.11M | 0.09% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 915,193 | 0.83% | $213.25M | 0.22% | Jul 31, 2026 |
| JPMorgan Mid Cap Value Fund | 787,236 | 0.71% | $166.85M | 1.49% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 781,999 | 0.71% | $165.74M | 0.41% | Jun 30, 2026 |
| T. Rowe Price U.S. Large-Cap Core Fund, Inc. | 781,314 | 0.71% | $165.60M | 0.92% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| J. E. Davis | CEO and President, Director | 122,423 | 0.11% | Sep 3, 2026 |
| Michael E. Prevoznik | SVP & General Counsel | 66,014 | 0.06% | Aug 31, 2026 |
| Mark E. Delaney | SVP & Chief Commercial Officer | 10,335 | 0.01% | Jul 29, 2026 |
| Patrick Plewman | SVP for Diagnostic Services | 15,293 | 0.01% | Jul 27, 2026 |
| Sam Samad | Executive Vice President & CFO | 33,478 | 0.03% | Jul 27, 2026 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 15,606 | 0.01% | Jul 27, 2026 |
| Catherine T. Doherty | EVP, Regional Businesses | 71,624 | 0.06% | Mar 6, 2026 |
| Michael J. Deppe | SVP, Corp. Controller & CAO | 35,902 | 0.03% | Mar 6, 2026 |
| Vicky B. Gregg | Director | 18,386 | 0.02% | Jul 27, 2026 |
| Timothy L. Main | Director | 27,460 | 0.02% | Jul 27, 2026 |
| Wright Lassiter III | Director | 10,323 | 0.01% | Jul 27, 2026 |
| Robert B. Carter | Director | 3,864 | 0.00% | Jul 27, 2026 |
| Timothy C. Wentworth | Director | 1,358 | 0.00% | Jul 2, 2026 |
| Denise M. Morrison | Director | 11,929 | 0.01% | May 21, 2026 |
| Timothy M. Ring | Director | 31,140 | 0.03% | May 21, 2026 |
| Gary M. Pfeiffer | Director | 31,005 | 0.03% | May 21, 2026 |
| Tracey Doi | Director | 7,748 | 0.01% | May 21, 2026 |
| Luis Diaz | Director | 5,196 | 0.00% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| J. E. Davis CEO and President, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −10,000 | $242.72 | $2.43M | 122,423 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Option exercise | +22,677 | $112.17 | $2.54M | 60,234 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −16,010 | $242.88 | $3.89M | 44,224 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −6,237 | $243.63 | $1.52M | 37,987 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −430 | $244.51 | $105.14K | 37,557 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Gift | −1,000 | – | – | 36,557 |
| Mark E. Delaney SVP & Chief Commercial Officer | Jul 28, 2026 | Sale(10b5-1 plan) | −1,600 | $235.18 | $376.29K | 10,335 |
| Vicky B. Gregg Director | Jul 22, 2026 | Award | +72 | $206.81 | $14.89K | 18,386 |
| Robert B. Carter Director | Jul 22, 2026 | Small purchase | +11 | $206.80 | $2.27K | 3,864 |
| Patrick Plewman SVP for Diagnostic Services | Jul 22, 2026 | Small purchase | +46 | $206.81 | $9.51K | 15,293 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jul 22, 2026 | Small purchase | +37 | $206.81 | $7.65K | 13,557 |
| Wright Lassiter III Director | Jul 22, 2026 | Small purchase | +6 | $206.81 | $1.24K | 10,323 |
| Mark E. Delaney SVP & Chief Commercial Officer | Jul 22, 2026 | Small purchase | +34 | $206.81 | $7.03K | 11,935 |
| Sam Samad Executive Vice President & CFO | Jul 22, 2026 | Award | +102 | $206.81 | $21.09K | 33,478 |
| Timothy L. Main Director | Jul 22, 2026 | Small purchase | +21 | $206.81 | $4.34K | 22,460 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Sale(10b5-1 plan) | −8,147 | $200.00 | $1.63M | 13,510 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Option exercise | +3,320 | $127.73 | $424.06K | 16,830 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Option exercise | +4,827 | $121.81 | $587.98K | 21,657 |
| J. E. Davis CEO and President, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −10,000 | $194.14 | $1.94M | 132,423 |
| Vicky B. Gregg Director | May 20, 2026 | Award | +1,142 | – | – | 18,314 |
| Timothy L. Main Director | May 20, 2026 | Award | +1,142 | – | – | 27,439 |
| Tracey Doi Director | May 20, 2026 | Award | +1,142 | – | – | 7,748 |
| Gary M. Pfeiffer Director | May 20, 2026 | Award | +1,142 | – | – | 31,005 |
| Robert B. Carter Director | May 20, 2026 | Award | +1,142 | – | – | 3,853 |
| Timothy C. Wentworth Director | May 20, 2026 | Award | +1,142 | – | – | 1,358 |
| Wright Lassiter III Director | May 20, 2026 | Award | +1,142 | – | – | 10,317 |
| Timothy M. Ring Director | May 20, 2026 | Award | +1,142 | – | – | 31,140 |
| Luis Diaz Director | May 20, 2026 | Award | +1,142 | – | – | 5,196 |
| Denise M. Morrison Director | May 20, 2026 | Award | +1,142 | – | – | 11,929 |
| Patrick Plewman SVP for Diagnostic Services | Apr 20, 2026 | Small purchase | +49 | $194.70 | $9.54K | 15,247 |
| Robert B. Carter Director | Apr 20, 2026 | Small purchase | +7 | $194.70 | $1.36K | 2,711 |
| Vicky B. Gregg Director | Apr 20, 2026 | Award | +68 | $194.70 | $13.24K | 17,172 |
| Sam Samad Executive Vice President & CFO | Apr 20, 2026 | Award | +108 | $194.70 | $21.03K | 33,376 |
| Wright Lassiter III Director | Apr 20, 2026 | Small purchase | +6 | $194.70 | $1.17K | 9,063 |
| Karthik Kuppusamy SVP, Clinical Solutions | Apr 20, 2026 | Small purchase | +39 | $194.70 | $7.59K | 13,490 |
| Mark E. Delaney SVP & Chief Commercial Officer | Apr 20, 2026 | Small purchase | +37 | $194.70 | $7.20K | 11,901 |
| Timothy C. Wentworth Director | Mar 9, 2026 | Award | +215 | – | – | 215 |
| Catherine T. Doherty EVP, Regional Businesses | Mar 5, 2026 | Sale(10b5-1 plan) | −5,558 | $206.21 | $1.15M | 67,122 |
| Patrick Plewman SVP for Diagnostic Services | Mar 5, 2026 | Sale(10b5-1 plan) | −2,855 | $206.21 | $588.73K | 15,198 |
| Michael E. Prevoznik SVP & General Counsel | Mar 5, 2026 | Sale(10b5-1 plan) | −3,878 | $206.21 | $799.68K | 37,557 |
| J. E. Davis CEO and President, Director | Mar 4, 2026 | Award | +51,652 | $204.86 | $10.58M | 168,837 |
| J. E. Davis CEO and President, Director | Mar 4, 2026 | Tax withholding | −26,414 | $204.86 | $5.41M | 142,423 |
| Catherine T. Doherty EVP, Regional Businesses | Mar 4, 2026 | Award | +11,364 | $204.86 | $2.33M | 78,486 |
| Catherine T. Doherty EVP, Regional Businesses | Mar 4, 2026 | Tax withholding | −5,806 | $204.86 | $1.19M | 72,680 |
| Mark E. Delaney SVP & Chief Commercial Officer | Mar 4, 2026 | Tax withholding | −2,326 | $204.86 | $476.50K | 11,864 |
| Mark E. Delaney SVP & Chief Commercial Officer | Mar 4, 2026 | Award | +5,682 | $204.86 | $1.16M | 14,190 |
| Sam Samad Executive Vice President & CFO | Mar 4, 2026 | Tax withholding | −7,720 | $204.86 | $1.58M | 33,268 |
| Sam Samad Executive Vice President & CFO | Mar 4, 2026 | Award | +13,947 | $204.86 | $2.86M | 40,988 |
| Patrick Plewman SVP for Diagnostic Services | Mar 4, 2026 | Award | +5,682 | $204.86 | $1.16M | 20,880 |
| Patrick Plewman SVP for Diagnostic Services | Mar 4, 2026 | Tax withholding | −2,827 | $204.86 | $579.14K | 18,053 |
| Michael J. Deppe SVP, Corp. Controller & CAO | Mar 4, 2026 | Tax withholding | −750 | $204.86 | $153.65K | 35,196 |
| Michael J. Deppe SVP, Corp. Controller & CAO | Mar 4, 2026 | Award | +1,473 | $204.86 | $301.76K | 35,946 |
| Karthik Kuppusamy SVP, Clinical Solutions | Mar 4, 2026 | Sale | −2,628 | $204.86 | $538.37K | 13,441 |
| Karthik Kuppusamy SVP, Clinical Solutions | Mar 4, 2026 | Award | +6,200 | $204.86 | $1.27M | 16,069 |
| Michael E. Prevoznik SVP & General Counsel | Mar 4, 2026 | Award | +7,232 | $204.86 | $1.48M | 44,789 |
| Michael E. Prevoznik SVP & General Counsel | Mar 4, 2026 | Tax withholding | −3,354 | $204.86 | $687.10K | 41,435 |
| Catherine T. Doherty EVP, Regional Businesses | Mar 3, 2026 | Sale(10b5-1 plan) | −632 | $207.73 | $131.29K | 67,122 |
| Patrick Plewman SVP for Diagnostic Services | Mar 3, 2026 | Sale(10b5-1 plan) | −410 | $207.73 | $85.17K | 15,198 |
| Michael E. Prevoznik SVP & General Counsel | Mar 3, 2026 | Sale(10b5-1 plan) | −526 | $207.73 | $109.27K | 37,557 |
| J. E. Davis CEO and President, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −10,000 | $212.52 | $2.13M | 117,185 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| J. E. Davis Officer, Director | Sep 1, 2026 | 10,000 | $2.43M | Sep 1, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Aug 28, 2026 | 22,677 | $5.51M | Aug 28, 2026 | Stock Option Exercise |
| Mark E. Delaney Officer | Jul 28, 2026 | 1,600 | $376.29K | Jul 28, 2026 | Restricted Stock Vesting |
| Karthik Kuppusamy Officer | Jun 4, 2026 | 8,147 | $1.63M | Jun 4, 2026 | Stock Option Exercise |
| J. E. Davis Officer, Director | Jun 1, 2026 | 10,000 | $1.94M | Jun 1, 2026 | Restricted Stock Vesting |
| Patrick Plewman Officer | Mar 5, 2026 | 2,855 | $588.73K | Mar 5, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Mar 5, 2026 | 5,558 | $1.15M | Mar 5, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Mar 5, 2026 | 3,878 | $799.68K | Mar 5, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Mar 3, 2026 | 526 | $109.27K | Mar 3, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Mar 3, 2026 | 632 | $131.29K | Mar 3, 2026 | Restricted Stock Vesting |
| Patrick Plewman Officer | Mar 3, 2026 | 410 | $85.17K | Mar 3, 2026 | Restricted Stock Vesting |
| J. E. Davis Officer, Director | Mar 2, 2026 | 10,000 | $2.13M | Mar 2, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Feb 19, 2026 | 1,111 | $227.57K | Feb 19, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Feb 19, 2026 | 1,433 | $293.52K | Feb 19, 2026 | Restricted Stock Vesting |
| Patrick Plewman Officer | Feb 19, 2026 | 958 | $196.23K | Feb 19, 2026 | Restricted Stock Vesting |